Pipeline
Biodefense
XOMA’s 30 years of antibody expertise and platform technologies for the development, scale-up and manufacture of monoclonal antibodies, make XOMA an ideal U.S. government partner to speed the advancement of therapies against emerging pathogenic threats.
XOMA 3AB, currently in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, is a first-in-class treatment for botulism poisoning. Preclinical and IND-enabling studies to date have shown that the XOMA 3AB candidate is well-tolerated and effective at neutralizing and clearing botulinum toxin (Type A) from the bloodstream in animals. To date, XOMA has entered approximately $120 million in U.S. government contracts for its botulism-related biodefense program.
In addition to XOMA 3AB, XOMA is using its proprietary antibody development and manufacturing platforms to produce and characterize antibody co-formulation therapeutic candidates designed to treat other botulinum toxin types by effectively removing toxin from the bloodstream.
Since 2005, XOMA has worked in partnership with NIAID, leveraging XOMA’s state-of-the art established antibody platforms to develop a portfolio of antibody therapeutics for the treatment of botulinum toxin (Type A, B, C, D and E) poisoning. To date, XOMA has entered into contracts with NIAID totaling approximately $120 million: Contract No. HHSN266200500004C, Contract No. HHSN266200600008C, Contract No. HHSN272200800028C, Contract No. HHSN266200600011C Contract No. HHSN272200800026C, and Contract # HHHSN272201100031C.
Scientific Presentations
Scientific presentations regarding XOMA’s proprietary technologies and platforms used to develop co-formulation therapeutic candidates designed to treat botulinum toxin poisoning:
- Development of a Lyophilized Formulation for XOMA 3AB
- Recombinant Monoclonal Antibody Based Anti_BoNT A Drug Product Antitoxin for Treatment of Type A, B and E Botulism
- Nonclinical Safety Evaluation of XOMA 3AB, A Novel Triple Monoclonal Antibody Drug Product Targeting Botulinum Toxin Type A, in Sprague-Dawley Rats
